BLB&B Advisors’s Gilead Sciences GILD Stock Holding History

BLB&B Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,637	Closed	-$221K	–	278
2024 Q3	$221K	Buy	+2,637	New	+$201K	0.01%	261
2019 Q3	–	Sell	-3,300	Closed	-$223K	–	284
2019 Q2	$223K	Sell	3,300 -360	-10%	-$23.7K	0.03%	255
2019 Q1	$238K	Hold	3,660	–	–	0.03%	249
2018 Q4	$229K	Hold	3,660	–	–	0.03%	248
2018 Q3	$283K	Sell	3,660 -1,400	-28%	-$106K	0.04%	249
2018 Q2	$358K	Hold	5,060	–	–	0.05%	214
2018 Q1	$381K	Hold	5,060	–	–	0.05%	211
2017 Q4	$362K	Buy	5,060 +1,245	+33%	+$94.5K	0.05%	215
2017 Q3	$309K	Buy	+3,815	New	+$292K	0.05%	226
2016 Q3	–	Sell	-2,842	Closed	-$237K	–	281
2016 Q2	$237K	Sell	2,842 -75	-3%	-$6.66K	0.04%	244
2016 Q1	$268K	Buy	+2,917	New	+$263K	0.05%	221

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BLB&B Advisors's GILD Position: Q4 2024 in Review

BLB&B Advisors sold out of Gilead Sciences (GILD) in Q4 2024, closing a stake of 2,637 shares — an estimated $221K sold.

BLB&B Advisors first reported a position in GILD in Q1 2016 and held it in 11 quarters. The position peaked at $381K in Q1 2018. 1,890 funds tracked by Wall St. Rank hold GILD as of Q4 2024.

BLB&B Advisors reported no remaining Gilead Sciences position as of Q4 2024 after selling out during the quarter.
BLB&B Advisors sold 2,637 Gilead Sciences shares in Q4 2024, an estimated $221K.
BLB&B Advisors first reported a position in Gilead Sciences in Q1 2016 and held it in 11 quarters.
BLB&B Advisors's Gilead Sciences position peaked at $381K in Q1 2018.
1,890 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.

Based on BLB&B Advisors's 13F filing for Q4 2024, filed 28 Jan 2025.